论文部分内容阅读
临床比较性试验已证实Norplant左旋18甲基炔诺酮(LNG)皮下埋植为高度有效及可接受的避孕方法,很多国家已将此列入计划生育计划中。作者在人口理事会避孕研究国际委员会协助下,进行了评价Norplant在哺乳期应用的首次临床研究。目的是评价Norplant皮下埋植对哺乳及婴儿生长的影响,本文主要是产后第一年的观察结果。资料与方法对象为要求母乳喂养的健康产妇,无慢性疾病或服药史,年龄18～35岁,产次1～3次,在医院授予正确按需要喂养的哺乳技术,以后在第7,20,30及55±天门诊随访。产后第55±3天随诊时接受Norplant皮下埋植或TCu380AgIUD治疗。Norplant由6支硅胶囊组成,每支含LNG34mg,开始100天内每日释放量约100μg,逐渐下降,从第2～7年使用期间维持30μg/日。治疗后第10
Clinical comparative trials have demonstrated that subcutaneous implantation of Norplant levonorgestrel 18 (LNG) as a highly effective and acceptable method of contraception has been included in family planning programs in many countries. With the assistance of the International Committee on Contraceptive Research of the Population Council, the authors conducted the first clinical study to evaluate Norplant’s use in lactation. The purpose of this study was to evaluate the effects of Norplant subcutaneous implanting on breastfeeding and infant growth. This article is mainly based on the first year postnatal observations. Materials and Methods Subjects are healthy maternal mothers who require breastfeeding, no chronic diseases or medication history, aged 18-35 years, producing 1 to 3 times, in the hospital granted breastfeeding technology correctly according to need, after the 7th, 30 and 55 ± days outpatient follow-up. At 55 ± 3 days postpartum, Norplant was implanted subcutaneously or treated with TCu380AgIUD. Norplant is composed of 6 silicon capsules, each containing 34 mg of LNG, with a daily release of about 100 μg in the first 100 days and a gradual decrease of 30 μg per day from the second to seventh years of use. After the treatment of 10